185 related articles for article (PubMed ID: 18670740)
1. Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients.
Guntekin U; Gunes Y; Tuncer M; Simsek H; Gunes A
Adv Ther; 2008 Aug; 25(8):775-86. PubMed ID: 18670740
[TBL] [Abstract][Full Text] [Related]
2. Short-term effects of cilazapril and atenolol on P-wave dispersion in patients with hypertension.
Tuncer M; Gunes Y; Guntekin U; Gumrukcuoglu HA; Eryonucu B
Adv Ther; 2008 Feb; 25(2):99-105. PubMed ID: 18297254
[TBL] [Abstract][Full Text] [Related]
3. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
4. The effect of rapid blood pressure control on P-wave dispersion in hypertensive urgency.
Karaca I; Durukan P; Dagli N; Yavuzkir M; Ikizceli I; Balin M
Adv Ther; 2008 Dec; 25(12):1303-14. PubMed ID: 19043679
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension.
Ubaid-Girioli S; Ferreira-Melo SE; Souza LA; Nogueira EA; Yugar-Toledo JC; Coca A; Moreno H
J Clin Hypertens (Greenwich); 2007 Oct; 9(10):770-4. PubMed ID: 17917504
[TBL] [Abstract][Full Text] [Related]
7. Irbesartan improves arterial compliance more than lisinopril.
Ali K; Rajkumar C; Fantin F; Schiff R; Bulpitt CJ
Vasc Health Risk Manag; 2009; 5(4):587-92. PubMed ID: 19649309
[TBL] [Abstract][Full Text] [Related]
8. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
[TBL] [Abstract][Full Text] [Related]
9. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.
Celik T; Iyisoy A; Kursaklioglu H; Yilmaz MI; Kose S; Kilic S; Amasyali B; Demirkol S; Isik E
Clin Cardiol; 2005 Jun; 28(6):298-302. PubMed ID: 16028466
[TBL] [Abstract][Full Text] [Related]
10. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
[TBL] [Abstract][Full Text] [Related]
11. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
12. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling.
Liu E; Xu Z; Li J; Yang S; Yang W; Li G
Int J Cardiol; 2011 Feb; 146(3):364-70. PubMed ID: 19732978
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan in patients with atrial fibrillation.
; Yusuf S; Healey JS; Pogue J; Chrolavicius S; Flather M; Hart RG; Hohnloser SH; Joyner CD; Pfeffer MA; Connolly SJ
N Engl J Med; 2011 Mar; 364(10):928-38. PubMed ID: 21388310
[TBL] [Abstract][Full Text] [Related]
14. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
Masaki M; Komamura K; Goda A; Hirotani S; Otsuka M; Nakabo A; Fukui M; Fujiwara S; Sugahara M; Lee-Kawabata M; Tsujino T; Koshiba M; Masuyama T
J Cardiol; 2014 Mar; 63(3):205-10. PubMed ID: 24060523
[TBL] [Abstract][Full Text] [Related]
16. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
[TBL] [Abstract][Full Text] [Related]
17. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
[TBL] [Abstract][Full Text] [Related]
18. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
[TBL] [Abstract][Full Text] [Related]
19. Role of irbesartan in prevention of post-coronary artery bypass graft atrial fibrillation.
El-Haddad MA; Zalawadiya SK; Awdallah H; Sabet S; El-Haddad HA; Mostafa A; Rashed A; El-Naggar W; Farag N; Saleb MA; Jacob S
Am J Cardiovasc Drugs; 2011 Aug; 11(4):277-84. PubMed ID: 21623642
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
